search

Active clinical trials for "Guillain-Barre Syndrome"

Results 21-30 of 59

Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre...

Guillain-Barre Syndrome

This study aims to determine the effects of Proprioceptive Neuromuscular Training on Sensory versus Motor Function in patients presenting with Guillain Barre Syndrome.

Completed10 enrollment criteria

RWE-based Treatment Patterns and Outcomes in CIDP

Chronic Inflammatory Demyelinating PolyneuropathyGuillain-Barre Syndrome1 more

To describe the demographics, clinical characteristics, treatment patterns and clinical outcomes of chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and heredofamilial amyloidosis (hATTR) adult patients at a single U.K. centre.

Not yet recruiting4 enrollment criteria

IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients

Guillain-Barre Syndrome

In this study, the investigators address the question: whether treatment with IVIG is superior to treatment using plasmapheresis for functional recovery of patients with GBS? Recovery was quantified using: The changes in the A-Clinical grading scale MRC ( medial research council sum score ) and B-overall neuropathy limitations scale as the primary outcome and the changes in Neurophysiological study 3 months after treatment as a secondary outcome. This information will be used to evaluate which treatment is more beneficial to GBS patients.

Completed5 enrollment criteria

Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome

Guillain-Barré Syndrome

This study will carry out to assess the efficacy of GB-0998 (intravenous immunoglobulin;400mg/kg/day for five days) in the treatment of the Guillain-Barré Syndrome based on the changes in Hughes Functional Grade (FG) as primary endpoint, and in addition, to assess the safety of GB-0998.

Completed15 enrollment criteria

Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients

Guillain-Barré Syndrome

Guillain-Barré syndrome (GBS) is the commonest form of acute flaccid paralysis and the incidence is high in low-income countries. In Bangladesh, most GBS patients are poor. Therefore patients cannot afford expensive specific treatments like intravenous immunoglobulin (IVIg) or plasmapheresis (PE) in part explaining the high mortality and disability compared to treated patients in high-income countries. Added difficulty in traditional PE is its unavailability and specialized device and manpower dependency. Most research in GBS has been conducted in high-income countries, largely in patients with a demyelinating form of GBS. Axonal form of GBS is common in low-income and Asian countries which has a different pathogenesis, clinical course and outcome than the demyelinating form. Very few therapeutic studies have been conducted in low-income countries due to expensive existing modalities of treatment. Here, the investigators propose SVPE as a treatment for GBS in patients from low-income countries. SVPE is relatively cheap, can be done at the bedside without any special device or electricity and eventually is expected to help poor severely affected GBS patients in underdeveloped and developing countries. The main outcomes will be the safety and feasibility of SVPE since this is yet to be established in the resource limited settings. To be able to evaluate the safety of SVPE, additional information will be acquired about the frequency of complications in non-GBS patients with a central line, treated during the same time period at the same study facility as the GBS patients. Severe sepsis due to central line associated blood stream infection and deep venous thrombosis in the limb where the central venous catheter will be inserted during or following the SVPE procedure, will be defined as severe adverse effect (SAE) and will be considered as primary outcome measure for safety. Blood, cerebrospinal fluid and other relevant biological specimens will be analysed for diagnosis and screening for infections. In addition clinical and neurological outcome assessment will be monitored until discharge of the patient from the hospital and up to four weeks since study entry. Confirmation of feasibility and safety, will eventually lead to a randomized control trial in future with a primary focus on the clinical efficacy of SVPE for the treatment of GBS in developing countries as an alternative for the conventional treatment with IVIg or PE.

Completed10 enrollment criteria

A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome

Guillain-Barre Syndrome

This is a Phase 3, prospective, multicenter, placebo controlled, double blind, randomized study to investigate the efficacy and safety of eculizumab in participants with severe GBS, defined using the Hughes Functional Grade (FG) scale as progressively deteriorating FG3 or FG4/FG5 within 2 weeks from onset of weakness due to GBS. This study will be conducted only at sites in Japan.

Completed11 enrollment criteria

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Guillain-Barré Syndrome

This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.

Completed13 enrollment criteria

Regional Citrate Anticoagulation in Plasma Exchange Treatment

Focal Segmental GlomerulosclerosisGuillain-Barre Syndrome

The investigators want to compare the efficacy of plasma exchange treatment with using two different citrates ( 4% and 15% ) as anticoagulants in plasma exchange treatment. The efficacy of plasma exchange treatment is better with using 15% trisodium citrate as anticoagulant during the plasma exchange procedure.

Completed3 enrollment criteria

Recovery of Visual Acuity in People With Vestibular Deficits

Vestibular NeuronitisVestibular Neuronitis2 more

The purpose of this study is to determine whether exercises relieve the symptoms of dizziness and imbalance in people with vestibular deficits and improves the ability to see clearly during head movements. We hypothesize that the performance of specific adaptation and substitution exercises will result in an improvement in visual acuity during head movements while those patients performing placebo exercises will show no improvement.

Completed7 enrollment criteria

Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome

Guillain-Barré Syndrome

Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Patients evaluate the Functional Grade(FG) and Arm Grade(AG) et al. As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by the start of the study treatment.

Completed17 enrollment criteria
1234...6

Need Help? Contact our team!


We'll reach out to this number within 24 hrs